跳至主要内容
临床试验/ISRCTN11058680
ISRCTN11058680进行中(未招募)未知

The randomised thoracoscopic talc poudrage and indwelling pleural catheters versus thoracoscopic talc poudrage only in malignant pleural effusion trial

orth Bristol NHS Trust0 个研究点目标入组 124 人开始时间: 2021年8月23日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
124

研究概览

简要总结

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37253535/ protocol (added 31/05/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Symptomatic pleural effusion and any of the following:
  • 1.1. Thoracoscopically confirmed evidence of malignant pleural disease (visible cancer at thoracoscopy) which requires talc poudrage as part of routine clinical care
  • 1.2. An established diagnosis of malignant pleural effusion (via biopsy or cytology) which requires drainage and pleurodesis as per standard care, where the patient/operator decide on a thoracoscopic treatment
  • 1.3. Symptomatic effusion requiring drainage and pleurodesis in the context of established metastatic disease
  • 2. Able to consent to trial inclusion

排除标准

  • 1. Technically unable to undergo thoracoscopy and talc poudrage (e.g. gross respiratory failure, uncorrectable clotting, unable to tolerate position, significant suspicion of underlying trapped lung or poor performance status)
  • 2. Visual impairment (precluding use of symptom measurement instruments)
  • 3. Previous talc pleurodesis within the last 3 months on ipsilateral side
  • 4. No means of phone contact
  • 5. Age <18 years
  • 6. Females who are pregnant or lactating
  • 7. Unable to consent to trial inclusion

研究者

发起方
orth Bristol NHS Trust

相似试验